by Raynovich Rod | Feb 24, 2016 | Biopharmaceuticals, Macro
Biotech Stocks Off Lows Tracking Crude and Energy sector… 11.45 a EST Can healthcare stocks uncouple from energy and macro? Individual biotech stocks look very tradable with green catching up with red. But biotech stocks defy fundamental analysis with current...
by Raynovich Rod | Feb 22, 2016 | Biopharmaceuticals
2/23 After Close—Energy Rout Burns Biotech Stocks and NASDAQ The red screen dominated except few winners like ZIOPHARM Oncology (ZIOP) up 13.95% on a publication regarding gene editing. Another gene editing stock and recent IPO Editas Medicine (EDIT) was up...
by Raynovich Rod | Feb 16, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
Rayno Large Cap Biopharmaceuticals…Part 2…A Stock pickers Market Time to Rebuild Your Portfolio: ABBV, BMY, GILD Below we have summarized selective metrics for large cap biopharmaceutical companies. We began the process of revising and rebalancing our...
by Raynovich Rod | Feb 10, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Macro
Have we reached a tradeable bottom in the biotech bear market? Today’s tape showed good volume but gains faded late in session. NASDAQ up 0.35% XLV up 0.88%-healthcare is the leading sector The biotech market bounced back early today in a broad rally...
by Raynovich Rod | Feb 3, 2016 | 2024 Rayno Biopharmaceuticals Portfolio, Biopharmaceuticals
2/5/16 …11:20 AM Biotechs Can’t Hold Gains …Drop Back Near 52 Week Lows Hit Wednesday IBB $261 XBI $48 Update-2 At Close 2/4/16…Nice Rally But Off Earlier Highs-Very Stock Specific A nice snap-back rally with a lot of green screen across the...
by Raynovich Rod | Feb 2, 2016 | 2024 Rayno Biopharmaceuticals Portfolio
Where is the Growth Potential in Large Cap Biopharmaceutical Companies? Caution: Risk Aversion Remains High Investing in biotech stocks ain’t getting easier. The sector is underperforming the market by 16% YTD, sentiment has been burned by concerns about drug...
by Raynovich Rod | Feb 1, 2016 | 2024 Rayno Tools and Diagnostics Portfolio
Abbott Laboratories Acquires Alere (ALR) -Stock Soars 45% At Market Opening Alere Product Line Offers Synergies and Boosts Global Diagnostics Presence 2015 Revenues of Alere Are Estimated in $2.5B Range So Deal is About 2.3X Sales Alere (ALR) has a broad-based product...